Chromatography ligand comprising domain C from Staphylococcus aureus protein A for antibody isolation

Patent metadata

Field	Value
Publication number	US-9663559-B2
Application number	US-201615063471-A
Country	US
Kind code	B2
Filing date	Mar 7, 2016
Priority date	Sep 29, 2006
Publication date	May 30, 2017
Grant date	May 30, 2017

Abstract

The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.

First claim

What is claimed is:

1. A process of isolating one or more target compounds, the process comprising,
contacting a liquid comprising said compound(s) with a chromatography matrix;
allowing said compound(s) to adsorb to ligands present on the matrix, wherein said ligands consist of one or more Staphylococcus protein A (SpA) Domain C variants; and,
optionally, eluting said compound(s) by passing across said matrix of a liquid that releases them from ligands,
wherein the one or more Staphylococcus protein A (SpA) Domain C variants comprises a sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 1 with mutation G29A, and SEQ ID NO: 2 with mutation G25A, and
wherein at least one asparagine in the sequence is replaced with an amino acid other than glutamine or aspartic acid.

2. A process of isolating one or more target compounds, the process comprising,
contacting a liquid comprising said compound(s) with a chromatography matrix;
allowing said compound(s) to adsorb to ligands present on the matrix, wherein said ligands are multimers comprising at least two Staphylococcus protein A (SpA) Domain C variants; and,
optionally, eluting said compound(s) by the passing across said matrix of a liquid that releases them from ligands,
wherein the at least two Staphylococcus protein A (SpA) Domain C variants comprises a sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 1 with mutation G29A, and SEQ ID NO: 2 with mutation G25A, and
wherein at least one asparagine in the sequence is replaced with an amino acid other than glutamine or aspartic acid.

3. A process of claim 1 , wherein the target compound is a protein, an antibody, or a Fab fragment.

4. The process of claim 1 , wherein the ligands present on the matrix have retained at least 95% of their original binding capacities after 5 hours incubation in 0.5 M NaOH.

5. The process of claim 1 , wherein the isolation process is repeated for 2-300 times, optionally with washing steps between.

6. The process of claim 5 , further comprising alkaline regeneration of the matrix followed optionally by performing another process of isolating one or more target compounds, the process comprising,
contacting a liquid comprising said compound(s) with a chromatography matrix;
allowing said compound(s) to adsorb to ligands present on the matrix, wherein said ligands consist of one or more Staphylococcus protein A (SpA) Domain C variants; and,
optionally, eluting said compound(s) by the passing across said matrix of a liquid that releases them from ligands.

7. The process of claim 6 , wherein regeneration is carried out by incubating the matrix with a sodium hydroxide solution.

8. The process of claim 7 , wherein the sodium hydroxide solution has a concentration of about 0.5 M.

9. The process of claim 2 , wherein the target compound is a protein, an antibody, or a Fab fragment.

10. The process of claim 2 , wherein in addition to said at least two Domain C units of the multimer, the matrix also comprises one or more other alkaline-stable protein-based units.

11. The process of claim 2 , wherein the multimer comprises 2-8 Domain C units, optionally coupled via linker segments.

12. The process of claim 2 , wherein the ligands present on the matrix have retained at least 95% of their original binding capacities after 5 hours incubation in 0.5 M NaOH.

13. The process of claim 2 , wherein the isolation process is repeated for 2-300 times, optionally with washing steps between.

14. The process of claim 13 , further comprising alkaline regeneration of the matrix followed optionally by performing another process of isolating one or more target compounds, the process comprising,
contacting a liquid comprising said compound(s) with a chromatography matrix;
allowing said compound(s) to adsorb to ligands present on the matrix, wherein said ligands are multimers comprising at least two Staphylococcus protein A (SpA) Domain C variants; and,
optionally, eluting said compound(s) by the passing across said matrix of a liquid that releases them from ligands.

15. The process of claim 14 , wherein regeneration is carried out by incubating the matrix with a sodium hydroxide solution.

16. The process of claim 15 , wherein the sodium hydroxide solution has a concentration of about 0.5 M.

17. A process of absorbing one or more immunoglobulins from a liquid, the process comprising,
contacting the liquid comprising said immunoglobulin(s) with an alkaline-stable immunoglobulin adsorbent;
allowing said immunoglobulin(s) to adsorb to ligands present on the alkaline-stable immunoglobulin adsorbent, wherein said ligands consist of one or more Staphylococcus protein A (SpA) Domain C variants, to remove said immunoglobulin(s) from the liquid,
wherein the one or more Staphylococcus protein A (SpA) Domain C variants comprises a sequence selected from SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO: 1 with mutation G29A, and SEQ ID NO: 2 with mutation G25A, and
wherein at least one asparagine in the sequence is replaced with an amino acid other than glutamine or aspartic acid.

18. A process of absorbing one or more a Fab fragments from a liquid, the process comprising,
contacting the liquid comprising said Fab fragment(s) with an alkaline-stable Fab fragment-binding adsorbent;
allowing said Fab fragment(s) to adsorb to ligands present on the alkaline-stable Fab fragment-binding adsorbent, wherein said ligands consist of one or more Staphylococcus protein A (SpA) Domain C variants, to remove said Fab fragment(s) from the liquid,
wherein the one or more Staphylococcus protein A (SpA) Domain C variants comprises a sequence selected from SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO: 1 with mutation G29A, and SEQ ID NO: 2 with mutation G25A, and
wherein at least one asparagine in the sequence is replaced with an amino acid other than glutamine or aspartic acid.

Assignees

• Ge Healthcare Bioprocess R&D Ab
• Ge Healthcare Bio Sciences Ab

Inventors

• Hall Martin
• Larsson Sture
• Muranyi Andreas
• Rodrigo Gustav
• Zou Jinyu
• Aberg Per-Mikael

Classifications

• C07K1/22

  Affinity chromatography or related techniques based upon selective absorption processes · CPC title

• B01J20/286

  Phases chemically bonded to a substrate, e.g. to silica or to polymers · CPC title

• C07K14/31 Primary

  from Staphylococcus (G) · CPC title

• C07K17/10

  the carrier being a carbohydrate · CPC title

• B01J20/3274

  Proteins, nucleic acids, polysaccharides, antibodies or antigens · CPC title